Literature DB >> 17301127

Epstein-Barr virus transcription activator Rta upregulates decoy receptor 3 expression by binding to its promoter.

Cheng-Hsun Ho1, Chen-Fang Hsu, Pei-Fen Fong, Shyh-Kuan Tai, Shie-Liang Hsieh, Chi-Ju Chen.   

Abstract

Decoy receptor 3 (DcR3) is a soluble decoy receptor belonging to the tumor necrosis factor receptor superfamily that is overexpressed in various malignant tumor types. DcR3 has been implicated in tumor cell survival by inhibiting apoptosis and by interfering with immune surveillance. A previous study showed that DcR3 expression is associated with Epstein-Barr virus (EBV)-positive lymphomas but rarely with non-EBV-positive B-cell lymphomas, suggesting that the presence of EBV may affect DcR3 expression. Here, we demonstrated enhanced DcR3 expression upon EBV reactivation in P3HR1 cells and in EBV-infected 293 cells. This enhancement, however, could not be detected in 293 cells infected with EBV with BRLF1 deleted. We found that EBV transactivator, Rta, could upregulate DcR3 expression by direct binding to an Rta-responsive element (RRE) located in the DcR3 promoter region and that this RRE is important for Rta-mediated DcR3 expression. Overexpressing CREB-binding protein (CBP) further enhanced Rta-dependent DcR3 expression, suggesting Rta-dependent DcR3 transcription activity is mediated by CBP. Previously, Rta was shown to enhance phosphatidylinositol-3 kinase (PI3-K) activity. However, Rta-transduced PI 3-K activity plays a minor role in DcR3 expression. This is the first report to demonstrate that Rta upregulates a cellular gene by direct binding to an RRE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301127      PMCID: PMC1900157          DOI: 10.1128/JVI.02448-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Characterization of the Epstein-Barr virus BALF2 promoter.

Authors:  Chien-Hui Hung; Shih-Tung Liu
Journal:  J Gen Virol       Date:  1999-10       Impact factor: 3.891

2.  Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites.

Authors:  T Ragoczy; G Miller
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Differential expression of LIGHT and its receptors in human placental villi and amniochorion membranes.

Authors:  Ryan M Gill; Jian Ni; Joan S Hunt
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

4.  Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency.

Authors:  C Rooney; N Taylor; J Countryman; H Jenson; J Kolman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

5.  A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals.

Authors:  Q Y Yao; A B Rickinson; M A Epstein
Journal:  Int J Cancer       Date:  1985-01-15       Impact factor: 7.396

6.  TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.

Authors:  Thi Sau Migone; Jun Zhang; Xia Luo; Li Zhuang; Cecil Chen; Bugen Hu; June S Hong; James W Perry; Su Fang Chen; Joe X H Zhou; Yun Hee Cho; Stephen Ullrich; Palanisamy Kanakaraj; Jeffrey Carrell; Ernest Boyd; Henrik S Olsen; Gang Hu; Laurie Pukac; Ding Liu; Jian Ni; Sunghee Kim; Reiner Gentz; Ping Feng; Paul A Moore; Steve M Ruben; Ping Wei
Journal:  Immunity       Date:  2002-03       Impact factor: 31.745

7.  Epstein-Barr virus immediate-early protein BRLF1 interacts with CBP, promoting enhanced BRLF1 transactivation.

Authors:  J J Swenson; E Holley-Guthrie; S C Kenney
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

8.  Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization.

Authors:  I Anagnostopoulos; H Herbst; G Niedobitek; H Stein
Journal:  Blood       Date:  1989-08-01       Impact factor: 22.113

9.  The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.

Authors:  Yasushi Takahama; Yukishige Yamada; Koji Emoto; Heisuke Fujimoto; Tomoyoshi Takayama; Masatoh Ueno; Hideki Uchida; Shuya Hirao; Takashi Mizuno; Yoshiyuki Nakajima
Journal:  Gastric Cancer       Date:  2002       Impact factor: 7.370

10.  Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma.

Authors:  Shoichiro Tsuji; Ryo Hosotani; Shin Yonehara; Toshihiko Masui; Sidhartha S Tulachan; Sanae Nakajima; Hiroyuki Kobayashi; Masayuki Koizumi; Eiji Toyoda; Daisuke Ito; Kazuhiro Kami; Tomohiko Mori; Koji Fujimoto; Ryuichiro Doi; Masayuki Imamura
Journal:  Int J Cancer       Date:  2003-08-10       Impact factor: 7.396

View more
  10 in total

Review 1.  Molecular mechanisms of soluble cytokine receptor generation.

Authors:  Stewart J Levine
Journal:  J Biol Chem       Date:  2008-04-01       Impact factor: 5.157

2.  Regulation of autophagic activation by Rta of Epstein-Barr virus via the extracellular signal-regulated kinase pathway.

Authors:  Chien-Hui Hung; Lee-Wen Chen; Wen-Hung Wang; Pey-Jium Chang; Ya-Fang Chiu; Chen-Chia Hung; Ying-Ju Lin; Jieh-Yuan Liou; Wan-Ju Tsai; Chia-Ling Hung; Shih-Tung Liu
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

3.  Clinical significance of decoy receptor 3 upregulation in patients with hepatitis B and liver fibrosis.

Authors:  Xiaoli Lou; Yanqiang Hou; Hui Cao; Jingjing Zhao; Fengting Zhu
Journal:  Oncol Lett       Date:  2018-05-21       Impact factor: 2.967

4.  Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells.

Authors:  Meichi Hsu; Shih-Yi Wu; Shih-Shin Chang; Ih-Jen Su; Ching-Hwa Tsai; Siao-Jing Lai; Ai-Li Shiau; Kenzo Takada; Yao Chang
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

5.  Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma.

Authors:  Lusheng Song; Minkyo Song; M Constanza Camargo; Jennifer Van Duine; Stacy Williams; Yunro Chung; Kyoung-Mee Kim; Jolanta Lissowska; Armands Sivins; Weimin Gao; Kailash Karthikeyan; Jin Park; Marcis Leja; Jeffrey I Cohen; Joshua LaBaer; Ji Qiu; Charles S Rabkin
Journal:  Gastric Cancer       Date:  2021-03-04       Impact factor: 7.701

Review 6.  Decoy receptor 3: an endogenous immunomodulator in cancer growth and inflammatory reactions.

Authors:  Shie-Liang Hsieh; Wan-Wan Lin
Journal:  J Biomed Sci       Date:  2017-06-19       Impact factor: 8.410

7.  Up-regulation of DcR3 in microbial toxins-stimulated HUVECs involves NF-κB signalling.

Authors:  Yanqiang Hou; Dongyu Liang; Yang Liu; Hongwei Chen; Xiaoli Lou
Journal:  BMC Biochem       Date:  2018-12-27       Impact factor: 4.059

8.  Transcriptional regulators of human oncoviruses: structural and functional implications for anticancer therapy.

Authors:  Ivona Nečasová; Martin Stojaspal; Edita Motyčáková; Tomáš Brom; Tomáš Janovič; Ctirad Hofr
Journal:  NAR Cancer       Date:  2022-03-03

9.  The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma.

Authors:  Daniel Weissinger; Katrin E Tagscherer; Stephan Macher-Göppinger; Axel Haferkamp; Nina Wagener; Wilfried Roth
Journal:  Mol Cancer       Date:  2013-10-10       Impact factor: 27.401

10.  DcR3 induces proliferation, migration, invasion, and EMT in gastric cancer cells via the PI3K/AKT/GSK-3β/β-catenin signaling pathway.

Authors:  Hua Ge; Chaojie Liang; Zhixia Li; Dali An; Shulin Ren; Chaosen Yue; Jixiang Wu
Journal:  Onco Targets Ther       Date:  2018-07-19       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.